Sensyne Health’s first reports encourage investors

0 mins. to read
Sensyne Health’s first reports encourage investors
Master Investor Magazine 46 cover

Never miss an issue of Master Investor Magazine – sign-up now for free!

Read the latest Master Investor Magazine

The share price of AIM-listed clinical AI specialist Sensyne Health (LON:SENS) rose by 8.97% to 170p (as of 15:20 GMT) after the company announced a number of research agreements with NHS trusts as well as a US health operator and Oxford University’s Big Data Institute.

CEO Lord Drayson commented: “I am pleased to report strong progress by Sensyne Health in our first reporting period as a public company, achieving a number of important milestones.

Our business development pipeline is showing good momentum and is on track to meet the objectives set out at our Initial Public Offering (“IPO”). The Company is in an excellent position to capitalise on the data assets and Clinical Artificial Intelligence capabilities provided by its equity partnerships with NHS Trusts and the University of Oxford in order to meet the growing world-wide demand for data-driven healthcare innovation“.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *